{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T12:46:57Z","timestamp":1772369217898,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T00:00:00Z","timestamp":1561075200000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1 U10 CA180822"],"award-info":[{"award-number":["1 U10 CA180822"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180868"],"award-info":[{"award-number":["U10CA180868"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.ygyno.2018.04.572","type":"journal-article","created":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T17:21:37Z","timestamp":1525540897000},"page":"9-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001)"],"prefix":"10.1016","volume":"150","author":[{"given":"Panagiotis A.","family":"Konstantinopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William E.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Farley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise S.","family":"Uyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9712-2140","authenticated-orcid":false,"given":"David M.","family":"Gershenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2018.04.572_bb0005","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ygyno.2012.04.021","article-title":"Clear cell carcinoma of the ovary: a review of the literature","volume":"126","author":"del Carmen","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.04.572_bb0010","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ygyno.2014.11.078","article-title":"Updates and emerging therapies for rare epithelial ovarian cancers: one size no longer fits all","volume":"136","author":"Groen","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.04.572_bb0015","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ygyno.2006.12.024","article-title":"Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary","volume":"105","author":"Crotzer","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.04.572_bb0020","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000065067","article-title":"Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary","volume":"62","author":"Itamochi","year":"2002","journal-title":"Oncology"},{"key":"10.1016\/j.ygyno.2018.04.572_bb0025","first-page":"281","article-title":"Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary","volume":"100","author":"Itamochi","year":"2002","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2018.04.572_bb0030","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1349-7006.2008.00747.x","article-title":"Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma","volume":"99","author":"Itamochi","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ygyno.2018.04.572_bb0035","first-page":"1193","article-title":"Clear cell carcinoma of the ovary: potential pathogenic mechanisms (review)","volume":"23","author":"Kajihara","year":"2010","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ygyno.2018.04.572_bb0040","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1091\/mbc.e03-05-0279","article-title":"Gene expression patterns in ovarian carcinomas","volume":"14","author":"Schaner","year":"2003","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.ygyno.2018.04.572_bb0045","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/modpathol.2011.70","article-title":"Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient","volume":"24","author":"Yamamoto","year":"2011","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2018.04.572_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057724","article-title":"Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis","volume":"8","author":"Yamashita","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2018.04.572_bb0055","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1158\/1078-0432.CCR-10-3314","article-title":"IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer","volume":"17","author":"Anglesio","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2018.04.572_bb0060","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ijc.22679","article-title":"Hypoxia can induce c-Met expression in glioma cells and enhance SF\/HGF-induced cell migration","volume":"121","author":"Eckerich","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.04.572_bb0065","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1535-6108(03)00085-0","article-title":"Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene","volume":"3","author":"Pennacchietti","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2018.04.572_bb0070","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/modpathol.2011.143","article-title":"Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas","volume":"25","author":"Yamamoto","year":"2011","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2018.04.572_bb0075","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2018.04.572_bb0080","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1158\/2159-8290.CD-11-0240","article-title":"Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors","volume":"2","author":"Sennino","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ygyno.2018.04.572_bb0085","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1476-4598-9-9","article-title":"Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells","volume":"9","author":"Zhang","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ygyno.2018.04.572_bb0090","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1158\/0008-5472.CAN-10-2527","article-title":"VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer","volume":"71","author":"You","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2018.04.572_bb0095","doi-asserted-by":"crossref","first-page":"13373","DOI":"10.1073\/pnas.1404848111","article-title":"Direct regulation of GAS6\/AXL signaling by HIF promotes renal metastasis through SRC and MET","volume":"111","author":"Rankin","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2018.04.572_bb0100","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.gore.2016.11.001","article-title":"Response to sunitinib (sutent) in chemotherapy refractory clear cell ovarian cancer","volume":"18","author":"Alifrangis","year":"2016","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/j.ygyno.2018.04.572_bb0105","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1525-1438.2007.01156.x","article-title":"Potential benefit of sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma","volume":"18","author":"Rauh-Hain","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"83","key":"10.1016\/j.ygyno.2018.04.572_bb0110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ejca.2017.06.018","article-title":"A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma","volume":"1","author":"Vergote","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.04.572_bb0115","series-title":"ASCO GI Cancer San Francisco, CA","article-title":"Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase III CELESTIAL trial","author":"Abou-Alfa","year":"2018"},{"key":"10.1016\/j.ygyno.2018.04.572_bb0120","first-page":"1","article-title":"Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer","volume":"6","author":"Hart","year":"2013","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ygyno.2018.04.572_bb0125","series-title":"Society of Gynecologic Oncology Meeting 2015. Chicago","article-title":"A phase II evaluation of sunitinib (SU11248) in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG oncology\/gynecologic oncology group (GOG) study","author":"Chan","year":"2015"},{"key":"10.1016\/j.ygyno.2018.04.572_bb0130","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2353\/ajpath.2009.081000","article-title":"Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma","volume":"174","author":"Kuo","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ygyno.2018.04.572_bb0135","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","article-title":"ARID1A mutations in endometriosis-associated ovarian carcinomas","volume":"363","author":"Wiegand","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2018.04.572_bb0140","first-page":"5697","article-title":"Overexpression of PI3K p110alpha contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts","volume":"9","author":"Ji","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ygyno.2018.04.572_bb0145","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1158\/0008-5472.CAN-10-1623","article-title":"Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors","volume":"71","author":"Qi","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2018.04.572_bb0150","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2018.04.572_bb0155","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2009.10.069","article-title":"When \u2018never-events\u2019 occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes","volume":"116","author":"Duska","year":"2009","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818308503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818308503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:39:39Z","timestamp":1758771579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825818308503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0090825818308503"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.04.572","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001)","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.04.572","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}